根据一份提交给美国证券交易委员会（SEC）的文件披露，Crinetics Pharmaceuticals Inc. 与福泰制药（Vertex Pharmaceuticals）之间的交易若在特定情况下被终止，前者可能需要向后者支付高达3.5047亿美元的终止费用。
该文件明确了触发这一巨额财务义务的具体情形。协议条款显示，这笔费用的支付并非自动生效，而是与特定的终止条件紧密挂钩。这为市场参与者和投资者提供了关于此次潜在合作背后财务安排的关键细节。
分析人士指出，如此高额的终止费用条款，通常旨在保障交易双方的重大利益，尤其是在涉及重大战略合作或收购谈判时。它既体现了交易的严肃性与承诺深度，也可能反映出双方对交易最终达成所赋予的高度价值与期待。然而，这也同时意味着，一旦协议因规定情形破裂，Crinetics Pharmaceuticals将面临显著的财务支出。
目前，市场正密切关注两家公司后续的动向以及该交易的具体进展。此类财务安排细节的公开，有助于投资者更全面地评估相关交易的风险与潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.